Affiliated Treatment Facilities
111 Colchester Avenue
Main Campus, Main Pavilion, Level 2
Burlington, VT 05401
01. Doctor Overview
Dr. Steven Ades is a medical oncologist at the the University of Vermont Medical Center and associate professor at the Larner College of Medicine at UVM in Burlington, Vermont. Dr. Ades has expertise in peritoneal mesothelioma, with a particular interest in radiation therapy for abdominal mesothelioma and supportive care for patients.
Dr. Ades has been involved in clinical research focusing on adjuvant therapies in multimodal treatment plans to improve patient outcomes. He has also helped research biomarkers, which could allow for earlier detection and diagnosis of many cancers, including mesothelioma. Dr. Ades has authored and co-authored over 40 articles and medical studies, which can be found in presitigious medical journals like the Journal of Clinical Oncology.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Mesothelioma and peritoneal mesothelioma, adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, carcinoid tumor, carcinoma, colon cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, genitourinary cancer, hematologic cancer, kidney cancer, liver cancer, neuroendocrine cancer, Non-Hodgkin’s lymphoma, oncology, pancreatic cancer, penile cancer, prostate cancer, rectal cancer, small intestine cancer, stomach cancer, testicular cancer and urethral cancer.
Certifications, Awards & Accolades: Board Member of the American Board of Internal Medicine for Internal Medicine and Board Member of American Board of Internal Medicine for Medical Oncology
Education & Experience:
- Graduate of McGill University
- Fellowship for Oncology at New England Medical Center Hospitals
- Residency for Internal Medicine at Kingston General Hospital
- Medical Degree from McGill University School of Medicine
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. Journal of Clinical Oncology. May 2018;36:15.
NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomarker Research. April 2018;6:15. doi: 10.1186/s40364-018-0129-8
Enhancing the Khorana Score: Traditional VTE Risk Factors Are Important in Predicting Long Term VTE Risk in Cancer Patients Initiating Chemotherapy. Blood. 2017; 130:753.